BioClinica shareholder calls for managment resignations

By Alexandria Pesic

- Last updated on GMT

Related tags: Stock

BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”

Nicusa CEO Paul Johnson made the comments in a letter last week, when he said a “flawed”​ corporate strategy is “destroying shareholder value” ​and causing investors to lose confidence in the clinical services provider.

For Nicusa, the crux of the problem seems to lie with BioClinica’s $30m investment in its eclinical business, the underperformance of which, they say, has not been explained due management’s reluctance to provide a financial breakdown.

The group suggested that integrating the eclinicals business with the firm’s “core” clinical trial imaging unit is proving more difficult and less harmonious than management might have anticipated, which they said “ calls into question the management of either the core imaging business or the eclinical strategy.”

Personal criticism

Nicusa’s criticism focused on the three executives who it said have “failed to demonstrate that there are any synergies between the two businesses.”

The group alleges that Dr Nowiki, the chairman of the board, was “co-opted by management, and has bought into a failed strategy,” ​adding “We do not believe he is qualified to be chairman.”

The stakeholders describe Weinstein as “the architect of multiple failed investment strategies,” ​accusing him of being unwilling to cooperate constructively with shareholders and holding him “personally responsible for the company’s failed and costly investment in CapMed​.”

Bioclinica CFO, Mr Kaminer, also finds himself in the firing line for, allegedly, failing to provide transparency into the performance of the company’s two businesses and being “unable to articulate the company’s financial strategy.”

According to Johnson, over the past five years BioClinica have managed to increase the company’s book value by 193 per cent from $17.0m to $52.6m, yet have only added 13.8 per cent to the stock price.

He also claimed that although BioClinica has almost tripled the money invested in the business, the stock price has barely altered.

BioClinica has since released a response to the shareholder letter, and Mark Weinstein, the firm’s CEO, has agreed to take part in an Outsourcing-Pharma podcast to discuss the matter further.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us

Products

View more

Webinars